Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»US News

    Moderna (MRNA) Q2 2025 earnings

    AdminBy AdminAugust 1, 2025 US News
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram
    Moderna (MRNA) Q2 2025 earnings

    Moderna logo is seen in Warsaw, Poland on April 9, 2025.

    Jakub Porzycki | Nurphoto | Getty Images

    Moderna on Friday lowered the high end of its 2025 revenue outlook due to a delay in vaccine shipments to the U.K., but beat Wall Street’s expectations for the second quarter as it works to cut costs.

    Shares of Moderna fell more than 5% in premarket trading on Friday.

    The biotech company now expects full-year revenue to come in between $1.5 billion and $2.2 billion, down $300 million at the top of that range. The results come a day after Moderna announced plans to slash 10% of its workforce, adding to a string of cost cuts as the company grapples with falling Covid vaccine sales and tries to bring more products to market. 

    In an interview, Moderna CFO Jamey Mock said instead of shipping spring Covid boosters to the U.K. at the end of this year, the company will send those jabs to the country in the first quarter of 2026. He said there is no change in the overall contract value between Moderna and the U.K. 

    “It’s just moving deliveries from our fiscal year end into their fiscal year end, which happens to be the first quarter of next year, to fulfill supply for the spring booster in the U.K.,” Mock said. 

    Also on Friday, the company said it lost less than analysts were expecting for the second quarter and posted revenue that topped estimates. 

    Here’s what Moderna reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

    • Loss per share: $2.13 vs. an expected loss of $2.97
    • Revenue: $142 million vs. $113 million expected

    Moderna posted second-quarter sales of $142 million, down 41% from the same period a year ago due to dwindling Covid vaccine sales. The vast majority of the second quarter revenue came from its Covid shot, which took in $114 million for the period. 

    That surpassed the $89 million that analysts were expecting for the period, according to StreetAccount estimates. 

    But the company said its vaccine for respiratory syncytial virus had “negligible” sales, compared with the $5.9 million that analysts were expecting, StreetAccount estimates said. 

    The company posted a net loss of $825 million, or $2.13 per share, for the second quarter. That compares with a net loss of $1.3 billion, or $3.33 per share, reported for the year-ago period.

    Mock said Moderna’s efforts to cut costs helped the company beat estimates for the quarter. He said the company’s second-quarter operating expenses fell 27% to $1.1 billion from $1.6 billion during the same period a year ago. 

    “If there’s anything to really read into, from a first half [of 2025] perspective, from a financial perspective, it’s on the cost side,” Mock said. 

    Read the original article here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Musk regrets nearly $500 million midterm elections spending, says hes not MAGA

    November 19, 2026

    In historic move, House Democrats nominate Hakeem Jeffries for speaker of the House

    November 18, 2026

    Federal Reserve's Cook refuses to participate in White House hearing

    November 17, 2026

    The advice Biden got from Mitt Romney, and other takeaways from his memoir

    November 17, 2026

    Lindsay Clancy gets new trial date

    November 16, 2026

    Apple launches an AI health tool as part of a research study

    November 16, 2026
    Popular Posts

    Interview with Aletheia von Gottlieb, Author of Love Off the Ice (Sweet Snowfall Kisses Book 1) – NewInBooks

    What Were Wearing: Friendsgiving

    In historic move, House Democrats nominate Hakeem Jeffries for speaker of the House

    Book Riots Deals of the Day for November 18, 2026

    Voyager 1 at one light-day: Historian revisits Golden Record's forgotten details

    DWTS Fans Discover Sneaky Loophole To Rig Votes For Favorite

    Categories
    • Books (2,456)
    • Business (3,449)
    • Events (34)
    • Film (1,062)
    • LifeStyle (2,922)
    • Music (2,796)
    • Politics (2,355)
    • Science (1,951)
    • Technology (1,817)
    • Television (3,628)
    • US News (3,293)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • ‘DWTS’ Robert Irwin Reveals Two Amazing Hidden Talents‘DWTS’ Robert Irwin Reveals Two Amazing Hidden Talents
    • Alex G and the Blue Nile’s Paul Buchanan to Score Jane Schoenbrun FilmAlex G and the Blue Nile’s Paul Buchanan to Score Jane Schoenbrun Film
    • CNN names former New York Times CEO Mark Thompson as its chief
    • Satellite terminal supplier CopaSAT storms into military marketSatellite terminal supplier CopaSAT storms into military market
    • Family offices stall deal-making during Iran conflictFamily offices stall deal-making during Iran conflict
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.